BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36821113)

  • 1. Association of Brain Metastases With Survival in Patients With Limited or Stable Extracranial Disease: A Systematic Review and Meta-analysis.
    Li AY; Gaebe K; Zulfiqar A; Lee G; Jerzak KJ; Sahgal A; Habbous S; Erickson AW; Das S
    JAMA Netw Open; 2023 Feb; 6(2):e230475. PubMed ID: 36821113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis.
    Erickson AW; Brastianos PK; Das S
    JAMA Netw Open; 2020 Mar; 3(3):e201617. PubMed ID: 32211870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases.
    Carpenter DJ; Leng J; Arshad M; Giles W; Kirkpatrick JP; Floyd SR; Chmura SJ; Salama JK; Hong JC
    JAMA Netw Open; 2023 Apr; 6(4):e2310117. PubMed ID: 37099292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis.
    Gaebe K; Li AY; Park A; Parmar A; Lok BH; Sahgal A; Chan KKW; Erickson AW; Das S
    Lancet Oncol; 2022 Jul; 23(7):931-939. PubMed ID: 35644163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and prognostic factors in single brain metastases from small-cell lung cancer.
    Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hörner-Rieber J; König L; Kappes J; Thomas M; Unterberg A; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
    Strahlenther Onkol; 2018 Feb; 194(2):98-106. PubMed ID: 29085978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
    Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment and prognostic factors for survival in ALK+ non-small cell lung cancer (NSCLC) patients with brain metastases in China.
    Li N; Xie M; Zhou Z; Sheng J; Yu X; Fan Y
    Thorac Cancer; 2023 Jan; 14(3):237-245. PubMed ID: 36411716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study.
    He Z; Liu J; Ma Y; Jiang H; Cui Z; Wang G; Wu Y; Liu J; Cai X; Qian J; Huang J; Zhang H; Li H
    Cancer Manag Res; 2021; 13():6101-6111. PubMed ID: 34377028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis.
    Brar K; Taslimi S; Ellenbogen Y; Deng J; Hou W; Moraes FY; Glantz M; Zacharia BE; Tan A; Ahluwalia MS; Khasraw M; Zadeh G; Mansouri A
    World Neurosurg; 2022 Feb; 158():e87-e102. PubMed ID: 34688937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.
    Li Z; Shen D; Zhang J; Zhang J; Yang F; Kong D; Kong J; Zhang A
    BMC Cancer; 2019 Nov; 19(1):1104. PubMed ID: 31727054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis.
    Poon I; Erler D; Dagan R; Redmond KJ; Foote M; Badellino S; Biswas T; Louie AV; Lee Y; Atenafu EG; Ricardi U; Sahgal A
    JAMA Netw Open; 2020 Nov; 3(11):e2026312. PubMed ID: 33196810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.